BIOHM
LIVE

Serial Number

87274467

Owner

BIOHM HEALTH INC.

Attorney

Brian E. Turung

First Use Date

Mar 1, 2017

Filing Date

Dec 20, 2016

Add to watchlist:

No watchlists yet
View on USPTO

BIOHM Trademark

Serial Number: 87274467 • Registration: 5531063

BIOHM is a trademark filed by BIOHM HEALTH INC. on December 20, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

BIOHM HEALTH INC. (51 trademarks)

425 LITERARY ROAD
CLEVELAND, OH 44113

Entity Type: 99

PathoBiome LLC (23 trademarks)

Suite 4500
Cleveland, OH 44115

Entity Type: 16

BIOHM HEALTH LLC (23 trademarks)

CLEVELAND, OH 44113

Entity Type: 16

Trademark Details

Filing Date

December 20, 2016

Registration Date

July 31, 2018

First Use Anywhere

March 1, 2017

First Use in Commerce

March 1, 2017

Published for Opposition

March 6, 2018

Goods & Services

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 2, 2025 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 2, 2025 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 31, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Jul 31, 2024 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 31, 2023 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 15, 2023 ASGN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 22, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 22, 2020 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Nov 22, 2020 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 22, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 22, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 22, 2020 COAR
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 30, 2019 ASGN
REGISTERED-PRINCIPAL REGISTER
Jul 31, 2018 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jun 26, 2018 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jun 25, 2018 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 31, 2018 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 31, 2018 AITU
USE AMENDMENT FILED
May 9, 2018 IUAF
TEAS STATEMENT OF USE RECEIVED
May 9, 2018 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 1, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 6, 2018 NPUB
PUBLISHED FOR OPPOSITION
Mar 6, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 14, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2018 CNSA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 4, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 4, 2017 GNSL
SUSPENSION LETTER WRITTEN
Nov 4, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 17, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 17, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 16, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 25, 2017 GNRN
NON-FINAL ACTION E-MAILED
Sep 25, 2017 GNRT
NON-FINAL ACTION WRITTEN
Sep 25, 2017 CNRT
REMOVE FROM TEASRF
Sep 25, 2017 RMRF
AMENDMENT FROM APPLICANT ENTERED
Aug 30, 2017 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 30, 2017 CRFA
ASSIGNED TO LIE
Aug 28, 2017 ALIE
PAPER RECEIVED
Aug 8, 2017 MAIL
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 17, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 17, 2017 GNSL
SUSPENSION LETTER WRITTEN
Jul 17, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 21, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 20, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 20, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 27, 2017 GNRN
NON-FINAL ACTION E-MAILED
Mar 27, 2017 GNRT
NON-FINAL ACTION WRITTEN
Mar 27, 2017 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 28, 2016 NWOS